ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $836,392 | +6.5% | 8,932 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $785,400 | +46.5% | 8,800 | +76.0% | 0.00% | 0.0% |
| Q1 2023 | $536,100 | +58.0% | 5,000 | +79.9% | 0.00% | – |
| Q4 2022 | $339,399 | -51.0% | 2,779 | -52.9% | 0.00% | -100.0% |
| Q1 2022 | $692,000 | +207.6% | 5,900 | +318.4% | 0.00% | – |
| Q3 2021 | $225,000 | -60.4% | 1,410 | -67.3% | 0.00% | – |
| Q2 2021 | $568,000 | +2.2% | 4,314 | +0.0% | 0.00% | – |
| Q1 2021 | $556,000 | -22.7% | 4,313 | +0.1% | 0.00% | – |
| Q4 2020 | $719,000 | +5.7% | 4,310 | -2.0% | 0.00% | – |
| Q3 2020 | $680,000 | -42.5% | 4,399 | -44.9% | 0.00% | -100.0% |
| Q2 2020 | $1,182,000 | +52.7% | 7,990 | +16.3% | 0.00% | 0.0% |
| Q1 2020 | $774,000 | -64.1% | 6,869 | -55.7% | 0.00% | -50.0% |
| Q4 2019 | $2,156,000 | +436.3% | 15,504 | +271.2% | 0.00% | – |
| Q3 2019 | $402,000 | +33.1% | 4,177 | -72.2% | 0.00% | – |
| Q3 2016 | $302,000 | +42.5% | 15,031 | -6.2% | 0.00% | – |
| Q2 2016 | $212,000 | +14.0% | 16,030 | +60.0% | 0.00% | – |
| Q1 2016 | $186,000 | -9.3% | 10,016 | -10.7% | 0.00% | – |
| Q4 2015 | $205,000 | – | 11,220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,046,832 | $240,912,000 | 24.02% |
| RA Capital Management | 4,132,442 | $486,388,000 | 20.97% |
| VHCP Management II, LLC | 504,210 | $59,346,000 | 17.36% |
| Ghost Tree Capital, LLC | 385,000 | $45,315,000 | 11.84% |
| Sofinnova Investments, Inc. | 998,538 | $117,528,000 | 11.33% |
| Foresite Capital Management IV, LLC | 245,424 | $28,886,000 | 10.38% |
| Avoro Capital Advisors LLC | 1,795,000 | $211,272,000 | 9.14% |
| Orbimed Advisors | 3,970,673 | $467,348,000 | 7.24% |
| Eventide Asset Management | 1,698,648 | $199,931,000 | 6.88% |
| Foresite Capital Management III, LLC | 204,088 | $24,021,000 | 6.25% |